User:Tilman Schirmer/Sandbox 201
From Proteopedia
(Difference between revisions)
(→1.4 Substrate binding site) |
(→1.5 Allosteric product binding site) |
||
| Line 38: | Line 38: | ||
=== 1.5 Allosteric product binding site === | === 1.5 Allosteric product binding site === | ||
| - | + | <applet load='2v0n' size='300' frame='true' align='right' caption='Insert caption here' /> | |
---- | ---- | ||
| Line 46: | Line 46: | ||
==== 1.5.2 Primary inhibition site (Ip) ==== | ==== 1.5.2 Primary inhibition site (Ip) ==== | ||
| + | |||
| + | <scene name='User:Tilman_Schirmer/Sandbox_201/Primary_inhibition_site/1'>primary inhibition site</scene> | ||
| + | |||
| + | <scene name='User:Tilman_Schirmer/Sandbox_201/Primary_inhibition_site_5gp/1'>primary inhibition site + 5GP</scene> | ||
---- | ---- | ||
Revision as of 12:14, 19 June 2009
Diguanylate cyclases
Contents |
1. PleD
1.1 Intro
1.2 Domain structure
1.3 Protomer
|
: , ,
1.4 Substrate binding site
|
1.5 Allosteric product binding site
|
1.5.1 C-di-GMP
1.5.2 Primary inhibition site (Ip)
1.5.3 Secondary inhibition site (Is)
1.6 Two conformations
non-activated (1w25)
activated (BeF3- modified; 2v0n)
|
|
1.7 Non-activated conformation
|
: , ,
1.8 Activated conformation
|
